Kinnate Biopharma Inc. (KNTE)
$3.99
Rating:
Recommendation:
-
| Symbol | KNTE |
|---|---|
| Price | $3.99 |
| Beta | 0.211 |
| Volume Avg. | 0.44M |
| Market Cap | 185.825M |
| Shares () | - |
| 52 Week Range | 2.32-15.86 |
| 1y Target Est | - |
| DCF Unlevered | KNTE DCF -> | |
|---|---|---|
| DCF Levered | KNTE LDCF -> | |
| ROE | -65.39% | Strong Sell |
| ROA | -61.06% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 9.11% | Neutral |
| P/E | -1.38 | Sell |
| P/B | 0.79 | Buy |
Latest KNTE news
About
Download (Excel)Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.